Ubs Group Ag Corcept Therapeutics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 178,196 shares of CORT stock, worth $9.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,196

Previous 166,377 7.1%

Holding current value

$9.35 Million

Previous $5.41 Million 52.51%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$29.51 - $46.26 $348,778 - $546,746	11,819 Added 7.1%	178,196 $8.24 Million
Q2 2024 Aug 13, 2024	SELL	$22.21 - $34.48 $65,674 - $101,957	-2,957 Reduced 1.75%	166,377 $5.41 Million
Q1 2024 May 13, 2024	BUY	$21.1 - $27.46 $765,930 - $996,798	36,300 Added 27.29%	169,334 $4.27 Million
Q4 2023 Feb 09, 2024	BUY	$24.82 - $32.88 $1.6 Million - $2.12 Million	64,483 Added 94.07%	133,034 $4.32 Million
Q3 2023 Nov 09, 2023	BUY	$21.97 - $33.8 $453,175 - $697,192	20,627 Added 43.04%	68,551 $1.87 Million
Q2 2023 Aug 11, 2023	BUY	$21.44 - $25.15 $289,289 - $339,348	13,493 Added 39.19%	47,924 $1.07 Million
Q1 2023 May 12, 2023	BUY	$19.2 - $24.47 $59,635 - $76,003	3,106 Added 9.92%	34,431 $745,000
Q4 2022 Feb 08, 2023	SELL	$19.95 - $29.96 $36,428 - $54,706	-1,826 Reduced 5.51%	31,325 $636,000
Q3 2022 Nov 10, 2022	BUY	$24.7 - $29.12 $24,576 - $28,974	995 Added 3.09%	33,151 $850,000
Q2 2022 Aug 10, 2022	SELL	$17.33 - $25.3 $3.65 Million - $5.33 Million	-210,835 Reduced 86.77%	32,156 $764,000
Q1 2022 May 16, 2022	BUY	$16.53 - $25.21 $56,449 - $86,092	3,415 Added 1.43%	242,991 $5.47 Million
Q4 2021 Feb 14, 2022	BUY	$17.1 - $23.34 $3.45 Million - $4.71 Million	201,964 Added 536.97%	239,576 $4.74 Million
Q3 2021 Nov 15, 2021	SELL	$19.68 - $22.53 $1.26 Million - $1.44 Million	-63,820 Reduced 62.92%	37,612 $741,000
Q2 2021 Aug 13, 2021	BUY	$19.97 - $24.43 $1.2 Million - $1.46 Million	59,863 Added 144.01%	101,432 $2.23 Million
Q1 2021 May 12, 2021	BUY	$23.49 - $30.56 $14,587 - $18,977	621 Added 1.52%	41,569 $989,000
Q4 2020 Feb 11, 2021	SELL	$16.78 - $27.3 $17,652 - $28,719	-1,052 Reduced 2.5%	40,948 $1.07 Million
Q3 2020 Nov 12, 2020	SELL	$12.46 - $19.98 $1.13 Million - $1.8 Million	-90,304 Reduced 68.25%	42,000 $731,000
Q2 2020 Jul 31, 2020	SELL	$11.0 - $18.26 $2.04 Million - $3.38 Million	-185,279 Reduced 58.34%	132,304 $2.23 Million
Q1 2020 May 01, 2020	BUY	$10.11 - $14.04 $577,948 - $802,610	57,166 Added 21.95%	317,583 $3.78 Million
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $1.28 Million - $1.8 Million	106,234 Added 68.9%	260,417 $3.15 Million
Q3 2019 Nov 14, 2019	BUY	$10.41 - $14.66 $32,000 - $45,064	3,074 Added 2.03%	154,183 $2.18 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $12.76 $810,673 - $1.06 Million	82,891 Added 121.51%	151,109 $1.69 Million
Q1 2019 May 14, 2019	SELL	$10.03 - $15.71 $383,085 - $600,027	-38,194 Reduced 35.89%	68,218 $801,000
Q4 2018 Feb 14, 2019	BUY	$11.29 - $17.19 $528,902 - $805,299	46,847 Added 78.65%	106,412 $1.42 Million
Q3 2018 Nov 14, 2018	SELL	$12.27 - $15.65 $444,627 - $567,109	-36,237 Reduced 37.82%	59,565 $835,000
Q2 2018 Aug 14, 2018	BUY	$15.3 - $19.69 $622,939 - $801,678	40,715 Added 73.91%	95,802 $1.51 Million
Q1 2018 May 15, 2018	SELL	$14.59 - $25.5 $51,079 - $89,275	-3,501 Reduced 5.98%	55,087 $906,000
Q4 2017 Feb 14, 2018	SELL	$15.77 - $20.72 $278,167 - $365,480	-17,639 Reduced 23.14%	58,588 $1.06 Million
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $124,881 - $195,952	10,153 Added 15.37%	76,227 $1.47 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-2,696 Reduced 3.92%	66,074 $779,000
Q1 2017 Nov 14, 2017	BUY	N/A	68,770	68,770 $754,000

Others Institutions Holding CORT

# of Institutions

346

Shares Held

86.1M

Call Options Held

1.12M

Put Options Held

667K

View Full List

About CORCEPT THERAPEUTICS INC

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.62B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

More about CORT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account